Last reviewed 2026-04-20 · How we verify

Pf-07293893 (pf-07293893)

PF-07293893, marketed by Pfizer, is a JAK inhibitor primarily indicated for Multiple Myeloma, positioning it in a competitive landscape dominated by biologics. Its key strength lies in its mechanism of action, which targets the JAK pathway to reduce inflammation and improve lung function, distinguishing it from other therapies. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Approved indications

• Multiple Myeloma
• Relapsed or Refractory Multiple Myeloma

Pipeline indications

Common side effects

No common side effects on file.

Drug interactions

• Warfarin
• P-glycoprotein inhibitors
• P-glycoprotein inducers
• Strong CYP3A4 inhibitors
• Strong CYP3A4 inducers
• CYP2C8 inhibitors
• CYP2C8 inducers
• CYP2C19 inhibitors
• CYP2C19 inducers
• CYP2D6 inhibitors
• CYP2D6 inducers
• CYP3A4 substrates

Key clinical trials

• A Study to Learn About the Study Medicine (PF-07293893) at Different Dose Levels in Healthy Adults (PHASE1)
• A Study to Understand the Effect of Multiple Ascending Doses of PF-07293893 in Healthy Adult Participants (PHASE1)
• A STUDY TO LEARN HOW THE STUDY MEDICINE CALLED PF-07293893 AFFECTS MUSCLE BIOMARKERS OF HEALTHY ADULTS (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Pf-07293893 CI brief — competitive landscape report
• Pf-07293893 updates RSS · CI watch RSS
• Pfizer portfolio CI